Achieving Targeted Combined Endpoints in Patients With Atopic Dermatitis: A Real‐World Study
The Journal of Dermatology · 2026
DOI: 10.1111/1346-8138.70369 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, 2026. Verfasst von Yun-Wen Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Immunology, and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Dermatologic Agents. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Taichung Veterans General Hospital, Taichung Veterans General Hospital and National Health Research Institutes.
Abstract (Originalsprache)
Real‐world evidence on the treat‐to‐target strategy in atopic dermatitis (AD) remains limited. To evaluate targeted combined endpoints in AD, we conducted a cross‐sectional study that included 100 adults with AD receiving treatment ≥ 6 months. Targeted endpoints included Patient Global Assessment (PGA) ≤ 2, Eczema Area and Severity Index (EASI) ≤ 7, visual analog scale (VAS) of pruritus ≤ 4, Patient Oriented Eczema Measure (POEM) ≤ 7, and Dermatology Life Quality Index (DLQI) ≤ 5. Logistic regression and receiver operating characteristic (ROC) curve analysis were performed to identify factors associated with achieving treatment targets. Latent class analysis (LCA) and principal component analysis (PCA) were performed to identify patient subgroups and data components. Only 30% met all five targeted endpoints. An increased age was associated with a higher probability of achieving all treatment targets (aOR: 1.04; 95% CI: 1.00–1.09). DLQI could favorably predict the achievement of all 5 treatment targets (AUROC: 0.93; 95% CI: 0.88, 0.97). Despite no significant differences across treatment groups, the proportion of patients achieving all targets was the highest in the dupilumab group, followed by the Janus kinase inhibitor (JAKi) group. LCA identified one subgroup of patients achieving favorable skin control but poor life quality. PCA showed that life quality‐related factors other than the severity of skin lesions explained the majority of variance. In conclusion, achievement of targeted combined endpoints in AD remains suboptimal, partly due to life quality‐related factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Allergy, Immunology, and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan.
- Division of General Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
- Department of Animal Science and Biotechnology, Tunghai University, Taichung, Taiwan.
- Division of Allergy, Center of Rheumatology & Immunology, China Medical University Hospital, Taichung, Taiwan.
- Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.
- Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
ORCID-Profile: Yun-Wen Chen, Tsai-Hung Yen, Yi-Ming Chen, Tsu-Yi Hsieh, Kuo-Tung Tang
Förderung
- Taichung Veterans General Hospital
- Taichung Veterans General Hospital and National Health Research Institutes
Zitieren
APA
Chen, Y. W., Chen, Y. H., Yen, T. H., Chen, Y. J., Wu, Y. D., Chen, Y. M., Lin, C. T., Hsieh, T. Y., Huang, W. N., & Tang, K. T. (2026). Achieving Targeted Combined Endpoints in Patients With Atopic Dermatitis: A Real‐World Study. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.70369
Vancouver
Chen YW, Chen YH, Yen TH, Chen YJ, Wu YD, Chen YM, et al. Achieving Targeted Combined Endpoints in Patients With Atopic Dermatitis: A Real‐World Study. The Journal of Dermatology. 2026. doi:10.1111/1346-8138.70369
BibTeX
@article{Chen2026,
author = {Chen, Yun-Wen and Chen, Yi-Hsing and Yen, Tsai-Hung and Chen, Yen-Ju and Wu, Yi-Da and Chen, Yi-Ming and Lin, Ching-Tsai and Hsieh, Tsu-Yi and Huang, Wen-Nan and Tang, Kuo-Tung},
title = {Achieving Targeted Combined Endpoints in Patients With Atopic Dermatitis: A Real‐World Study},
journal = {The Journal of Dermatology},
year = {2026},
doi = {10.1111/1346-8138.70369}
}
EUVIMED